Clinical Trial Update: Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. [Phase 2]

View source ↗

Summary

Phase 2 trial assessing the safety and effectiveness of AZD4017, an 11b-Hydroxysteroid Dehydrogenase Type 1 inhibitor, for idiopathic intracranial hypertension;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Idiopathic Intracranial Hypertension

Drugs mentioned

• AZD4017

Snippet

Sponsor: University of Birmingham | Conditions: Idiopathic Intracranial Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2021-10-27